Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 13/20 | 0.46 |
| ▸ | MMP2 | P08253 | 11/20 | 0.46 |
| ▸ | MMP1 | P03956 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GRK2 | P25098 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133772 | 0.90 | MMP13 (0.56) | MMP13MMP2MMP1 | |
| SCHEMBL1133818 | 0.89 | MMP13 (0.44) | MMP13MMP2MMP1ALDH1A1POLB | |
| SCHEMBL2195902 | 0.89 | MMP13 (0.45) | MMP13MMP2MMP1ALDH1A1POLB | |
| SCHEMBL2197069 | 0.81 | MMP13 (0.39) | MMP13MMP2MMP1ALDH1A1POLB | |
| SCHEMBL5908693 | 0.73 | PLCG1 (0.47) | ALDH1A1POLBSMN1; SMN2LMNAKMT2A | |
| SCHEMBL1134049 | 0.72 | ALDH1A1 (0.41) | MMP13MMP2MMP1ALDH1A1POLB | |
| SCHEMBL2194247 | 0.72 | SMN1; SMN2 (0.49) | MMP13MMP2MMP1ALDH1A1POLB | |
| SCHEMBL19450297 | 0.72 | MMP2 (0.56) | MMP13MMP2MMP1ALDH1A1POLB | |
| SCHEMBL14238298 | 0.72 | PYCR1 (0.44) | ALDH1A1SMN1; SMN2MEN1LMNAGAA | |
| SCHEMBL7017241 | 0.71 | KMT2A (0.54) | MMP2ALDH1A1POLBMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524194-B2 | Radiolabelled MMP selective compounds | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2013-09-03 | — | — | US | disclosed |
| US-20110171133-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171133-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | MMP1, MMP3, MMP9 | MMP13 11/4885MMP2 4/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.